291 related articles for article (PubMed ID: 26235183)
1. Next revolution in molecular theranostics: personalized medicine for urologic cancers.
Aoun F; Kourie HR; Artigas C; Roumeguère T
Future Oncol; 2015; 11(15):2205-19. PubMed ID: 26235183
[TBL] [Abstract][Full Text] [Related]
2. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
Plichta KA; Graves SA; Buatti JM
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
[TBL] [Abstract][Full Text] [Related]
3. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
[TBL] [Abstract][Full Text] [Related]
4. Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Ambrosio MR; Di Serio C; Danza G; Rocca BJ; Ginori A; Prudovsky I; Marchionni N; Del Vecchio MT; Tarantini F
Diagn Pathol; 2016 May; 11(1):45. PubMed ID: 27225200
[TBL] [Abstract][Full Text] [Related]
5. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
Emmett L
Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
[TBL] [Abstract][Full Text] [Related]
6. The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation.
Miyahira AK; Soule HR
J Nucl Med; 2022 Mar; 63(3):331-338. PubMed ID: 34675109
[TBL] [Abstract][Full Text] [Related]
7. [Significance of prostate-specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase].
Heston WD
Urologe A; 1996 Sep; 35(5):400-7. PubMed ID: 8999630
[TBL] [Abstract][Full Text] [Related]
8. [Significance of current bio- and molecular-markers in urological cancers].
Shimazui T; Akaza H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA in prostate, bladder, and kidney cancer.
Martens-Uzunova ES; Böttcher R; Croce CM; Jenster G; Visakorpi T; Calin GA
Eur Urol; 2014 Jun; 65(6):1140-51. PubMed ID: 24373479
[TBL] [Abstract][Full Text] [Related]
10. Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.
Oosterwijk E
Subcell Biochem; 2014; 75():181-98. PubMed ID: 24146380
[TBL] [Abstract][Full Text] [Related]
11. Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers.
Malentacchi F; Vinci S; Melina AD; Kuncova J; Villari D; Nesi G; Selli C; Orlando C; Pazzagli M; Pinzani P
Urol Oncol; 2016 Jul; 34(7):292.e9-292.e16. PubMed ID: 27005925
[TBL] [Abstract][Full Text] [Related]
12. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness.
Panelli MC; Wang E; Marincola FM
Clin Cancer Res; 2005 May; 11(10):3601-3. PubMed ID: 15897553
[No Abstract] [Full Text] [Related]
13. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer.
Maurer T; Schwamborn K; Schottelius M; Wester HJ; Schwaiger M; Gschwend JE; Eiber M
Clin Genitourin Cancer; 2016 Oct; 14(5):e549-e552. PubMed ID: 27318956
[No Abstract] [Full Text] [Related]
14. The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder.
Klatte T; Belldegrun AS; Pantuck AJ
BJU Int; 2008 Jun; 101 Suppl 4():45-8. PubMed ID: 18430124
[No Abstract] [Full Text] [Related]
15. [Monoclonal antibodies in diagnosis and therapy].
Huland H; Hammerer P
Immun Infekt; 1989 Feb; 17(1):28. PubMed ID: 2647624
[TBL] [Abstract][Full Text] [Related]
16. Carbonic anhydrase IX expression in prostate cancer.
Smyth LG; O'Hurley G; O'Grady A; Fitzpatrick JM; Kay E; Watson RW
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):178-81. PubMed ID: 20038959
[TBL] [Abstract][Full Text] [Related]
17. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Kawaoka K; Wong SG; Belldegrun AS; Pantuck AJ
Cancer; 2009 Apr; 115(7):1448-58. PubMed ID: 19195047
[TBL] [Abstract][Full Text] [Related]
18. Urine microRNAs as potential noninvasive biomarkers in urologic cancers.
Mlcochova H; Hezova R; Stanik M; Slaby O
Urol Oncol; 2014 Jan; 32(1):41.e1-9. PubMed ID: 24035473
[TBL] [Abstract][Full Text] [Related]
19. PSMA expression is highly homogenous in primary prostate cancer.
Tsourlakis MC; Klein F; Kluth M; Quaas A; Graefen M; Haese A; Simon R; Sauter G; Schlomm T; Minner S
Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):449-55. PubMed ID: 26153794
[TBL] [Abstract][Full Text] [Related]
20. Annual review issue: Urologic pathology: a remarkable journey of innovation.
Cheng L; Berney DM
Histopathology; 2019 Jan; 74(1):3. PubMed ID: 30565305
[No Abstract] [Full Text] [Related]
[Next] [New Search]
